Cardinal Health 414 Company Profile

What is the competitive landscape for CARDINAL HEALTH 414

CARDINAL HEALTH 414 has five approved drugs.

There are two US patents protecting CARDINAL HEALTH 414 drugs.

There are thirty patent family members on CARDINAL HEALTH 414 drugs in twelve countries and seventy-one supplementary protection certificates in nine countries.

Summary for Cardinal Health 414

International Patents:	30
US Patents:	2
Tradenames:	5
Ingredients:	5
NDAs:	5

Drugs and US Patents for Cardinal Health 414

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cardinal Health 414	FLUDEOXYGLUCOSE F18	fludeoxyglucose f-18	INJECTABLE;INTRAVENOUS	203603-002	Sep 27, 2018	AP	RX	No	Yes
Cardinal Health 414	FLUDEOXYGLUCOSE F18	fludeoxyglucose f-18	INJECTABLE;INTRAVENOUS	203603-001	Nov 13, 2015	AP	RX	No	No
Cardinal Health 414	LYMPHOSEEK KIT	technetium tc-99m tilmanocept	INJECTABLE;INJECTION	202207-001	Mar 13, 2013		RX	Yes	Yes	6,409,990			Y
Cardinal Health 414	LYMPHOSEEK KIT	technetium tc-99m tilmanocept	INJECTABLE;INJECTION	202207-001	Mar 13, 2013		RX	Yes	Yes	9,439,985		Y
Cardinal Health 414	SODIUM FLUORIDE F-18	sodium fluoride f-18	INJECTABLE;INTRAVENOUS	203780-001	Jul 30, 2015	AP	RX	No	No
Cardinal Health 414	TECHNETIUM TC 99M SESTAMIBI	technetium tc-99m sestamibi kit	INJECTABLE;INJECTION	078809-001	Apr 28, 2009	AP	RX	No	No
Cardinal Health 414	TECHNETIUM TC-99M MEDRONATE KIT	technetium tc-99m medronate kit	INJECTABLE;INJECTION	018107-001	Approved Prior to Jan 1, 1982	AP	RX	No	No

International Patents for Cardinal Health 414 Drugs

Country	Patent Number	Estimated Expiration
Austria	277642
China	102301429
Japan	4056701
Japan	5743905
Japan	6509796
Netherlands	300736
South Korea	101713559

Supplementary Protection Certificates for Cardinal Health 414 Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822954	1890030-8	Sweden		PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
2380576	20C1048	France		PRODUCT NAME: SEL DE SODIUM DE L'ACIDE DESOXYCHOLIQUE; NAT. REGISTRATION NO/DATE: NL46299 20180810; FIRST REGISTRATION: IS - IS/1/16/071/01 20160729
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
1948158	93075	Luxembourg		PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE SODIQUE SACUBITRIL VALSARTAN, C'EST-A-DIRE DE (3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3'-METHYL-2-(PENTANYOL(2''-(TETRAZOL-5-YLATE)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRATE) DE TRISODIUM HEMIPENTAHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
1856135	CR 2020 00018	Denmark		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113
0186405	SPC/GB00/021	United Kingdom		PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
0957929	SPC/GB06/021	United Kingdom		PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cardinal Health 414
• Cardinal Health 418
• Cardinal Hlth 414

Pharmaceutical Competitive Landscape Analysis: Cardinal Health 414 – Market Position, Strengths & Strategic Insights

Cardinal Health, a leading player in the pharmaceutical distribution and healthcare services industry, has established a strong market position through its Cardinal Health 414 division. This comprehensive analysis delves into the company's competitive landscape, examining its market position, strengths, and strategic insights that drive its success in the pharmaceutical sector.

Cardinal Health 414: An Overview

Cardinal Health 414 is a key division within Cardinal Health's Pharmaceutical segment, focusing on the distribution of specialty pharmaceutical products and services. This division plays a crucial role in the company's overall strategy, catering to the growing demand for specialized medications and healthcare solutions.

Historical Context

Cardinal Health's journey in the pharmaceutical industry spans over five decades, with the company evolving from a regional drug wholesaler to a global healthcare services and products provider. The establishment of Cardinal Health 414 marked a significant milestone in the company's commitment to addressing the unique needs of specialty pharmaceutical distribution.

Core Offerings

Cardinal Health 414 specializes in:

1. Specialty pharmaceutical distribution
2. Oncology and other specialty practices support
3. Nuclear pharmacy services
4. Radiopharmaceutical manufacturing

Market Position and Share

Cardinal Health has solidified its position as one of the top three pharmaceutical wholesalers in the United States, alongside McKesson and AmerisourceBergen. As of the fourth quarter of 2024, Cardinal Health held a market share of 17.86% in the Pharmacy Services & Retail Drugstore industry[2].

Cardinal Health Inc's market share in the Pharmacy Services & Retail Drugstore industry stood at 17.86% for the 12 months ending Q4 2024, demonstrating its significant presence in the sector[2].

Competitive Landscape

The pharmaceutical distribution market is highly competitive, with key players vying for market share and strategic partnerships. Cardinal Health's main competitors include:

1. McKesson Corporation
2. AmerisourceBergen Corporation
3. CVS Health Corporation
4. Cencora Inc

These companies collectively dominate the market, with McKesson and CVS Health holding slightly larger market shares of 27.70% and 29.65%, respectively, as of Q4 2024[2].

Cardinal Health 414's Strengths

Extensive Distribution Network

Cardinal Health boasts a robust distribution network that spans across the United States and extends to international markets. This extensive reach allows the company to efficiently deliver pharmaceutical products to a wide range of healthcare providers, including hospitals, pharmacies, and specialty clinics.

Diverse Product Portfolio

The company's strength lies in its diverse product offerings, which include both branded and generic pharmaceuticals, as well as specialty medications. This diversification helps mitigate risks associated with market fluctuations and regulatory changes.

Innovative Technology Solutions

Cardinal Health has invested heavily in technology-driven solutions to enhance its distribution capabilities. These innovations include:

1. Inventory management systems
2. Real-time tracking of pharmaceutical shipments
3. Data analytics for demand forecasting

Strong Partnerships and Acquisitions

Strategic partnerships and acquisitions have played a crucial role in Cardinal Health's growth strategy. Notable examples include:

1. The acquisition of Specialty Networks in fiscal year 2024 for $1.2 billion, enhancing the company's specialty distribution capabilities[1].
2. The joint venture with CVS Health, Red Oak Sourcing, which strengthens Cardinal Health's sourcing capabilities and competitive edge[6].

Strategic Insights and Future Outlook

Focus on Specialty Pharmaceuticals

Cardinal Health 414 has strategically positioned itself to capitalize on the growing specialty pharmaceuticals market. This segment is expected to continue its rapid expansion due to:

1. Increasing prevalence of chronic diseases
2. Advancements in personalized medicine
3. Rising demand for oncology treatments

Expansion into Emerging Markets

While Cardinal Health has a strong presence in the United States, the company is actively pursuing growth opportunities in emerging markets. This strategy aims to:

1. Diversify revenue streams
2. Tap into high-growth regions
3. Mitigate risks associated with dependence on a single market

Investments in Digital Health Solutions

Cardinal Health is investing in digital health solutions to enhance its service offerings and improve operational efficiency. Key focus areas include:

1. Telemedicine platforms
2. Electronic health records integration
3. Artificial intelligence for supply chain optimization

Sustainability Initiatives

In line with growing environmental concerns, Cardinal Health has implemented sustainability initiatives across its operations. These efforts include:

1. Reducing carbon emissions in distribution networks
2. Implementing eco-friendly packaging solutions
3. Promoting responsible disposal of pharmaceutical waste

Financial Performance and Growth Projections

Cardinal Health's financial performance reflects its strong market position and strategic initiatives. In fiscal year 2024, the company reported:

1. Total revenues of $226.8 billion, an 11% increase from the previous year
2. GAAP earnings per share of $3.45
3. Non-GAAP diluted earnings per share of $7.53, representing a 29% growth[1]

Segment Performance

The Pharmaceutical and Specialty Solutions segment, which includes Cardinal Health 414, demonstrated robust growth:

1. Segment profit increased by 7%, exceeding the company's long-term targeted growth rate
2. The acquisition of Specialty Networks is expected to further accelerate growth in key specialty therapeutic areas[1]

Future Outlook

Cardinal Health has raised its fiscal year 2025 guidance, indicating confidence in its growth trajectory. The company's strategic focus on core businesses and accelerated growth in key areas positions it well for future success in the pharmaceutical distribution landscape.

Challenges and Mitigation Strategies

Despite its strong market position, Cardinal Health faces several challenges:

Regulatory Compliance

The pharmaceutical industry is heavily regulated, requiring constant vigilance to ensure compliance with evolving laws and regulations. Cardinal Health addresses this challenge through:

1. Robust compliance programs
2. Regular staff training on regulatory requirements
3. Proactive engagement with regulatory bodies

Pricing Pressures

Increasing competition and government initiatives to reduce healthcare costs have led to pricing pressures in the pharmaceutical distribution sector. Cardinal Health mitigates this challenge by:

1. Focusing on operational efficiency to reduce costs
2. Diversifying its product portfolio to include higher-margin specialty pharmaceuticals
3. Leveraging its scale to negotiate favorable terms with suppliers

Technological Disruption

The rapid pace of technological advancement poses both opportunities and threats to established players like Cardinal Health. The company's response includes:

1. Investments in digital transformation initiatives
2. Partnerships with tech startups to drive innovation
3. Continuous improvement of its IT infrastructure to enhance cybersecurity and data protection

Key Takeaways

1. Cardinal Health 414 holds a significant market share in the pharmaceutical distribution industry, with a strong focus on specialty pharmaceuticals.
2. The company's extensive distribution network, diverse product portfolio, and strategic acquisitions contribute to its competitive advantage.
3. Cardinal Health is actively pursuing growth opportunities in specialty pharmaceuticals, emerging markets, and digital health solutions.
4. Financial performance remains strong, with the company raising its fiscal year 2025 guidance.
5. Challenges such as regulatory compliance, pricing pressures, and technological disruption are being addressed through strategic initiatives and investments.

FAQs

1. What is Cardinal Health 414's primary focus within the pharmaceutical industry? Cardinal Health 414 primarily focuses on specialty pharmaceutical distribution, oncology and specialty practices support, nuclear pharmacy services, and radiopharmaceutical manufacturing.

2. How does Cardinal Health's market share compare to its main competitors? As of Q4 2024, Cardinal Health held a 17.86% market share in the Pharmacy Services & Retail Drugstore industry, compared to McKesson's 27.70% and CVS Health's 29.65%.

3. What recent acquisition has strengthened Cardinal Health's position in specialty pharmaceuticals? In fiscal year 2024, Cardinal Health acquired Specialty Networks for $1.2 billion, enhancing its capabilities in key specialty therapeutic areas.

4. How is Cardinal Health addressing the challenge of technological disruption? The company is investing in digital transformation initiatives, partnering with tech startups, and continuously improving its IT infrastructure to enhance cybersecurity and data protection.

5. What are Cardinal Health's key strategies for future growth? Cardinal Health is focusing on expanding its specialty pharmaceuticals business, entering emerging markets, investing in digital health solutions, and implementing sustainability initiatives to drive future growth.

Sources cited: [1] https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-FY24-annual-report.pdf [2] https://csimarket.com/stocks/competitionSEG2.php?code=CAH [6] https://www.gurufocus.com/news/2675106/decoding-cardinal-health-inc-cah-a-strategic-swot-insight